Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant effects » significantly affected (Expand Search)
significant effect » significant impact (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant effects » significantly affected (Expand Search)
significant effect » significant impact (Expand Search)
-
2681
-
2682
-
2683
-
2684
-
2685
-
2686
Sociodemographic characteristics of participants at baseline, overall and by age group.
Published 2025Subjects: -
2687
-
2688
-
2689
-
2690
-
2691
Moderating effect of CSR-sensitivity (RCSR).
Published 2025“…This study employs fixed-effects models for a panel data. The findings reveal that minimum wage increases are significantly associated with a reduction in both strategic CSR and responsive CSR. …”
-
2692
Moderating effect of CSR-sensitivity (SCSR).
Published 2025“…This study employs fixed-effects models for a panel data. The findings reveal that minimum wage increases are significantly associated with a reduction in both strategic CSR and responsive CSR. …”
-
2693
-
2694
Effects of intracisternal drug administration on the immunoreactivity of D2 receptor.
Published 2025“…N = 5 in each group. A significant decrease was found in the ION-CCI + CGRP Ab group as compared to the ION-CCI, ION-CCI + vehi, ION-CCI + CGRP, and ION-CCI + ctrl IgG groups. ** <i>p</i> < 0.01, * <i>p</i> < 0.05 compared to ION-CCI + CGRP Ab group. …”
-
2695
-
2696
-
2697
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
2698
-
2699
-
2700
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”